TY - JOUR
T1 - Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis
AU - Oh, Jiwon
AU - O'Connor, Paul W.
N1 - Funding Information:
Funding Dr. Jiwon Oh and Dr. O’Connor have received grant support from the MS Society of Canada.
PY - 2013/8
Y1 - 2013/8
N2 - Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
AB - Treatment options for relapsing-remitting multiple sclerosis (RRMS) have been continuously expanding in recent years, and the emergence of a number of oral disease-modifying agents (DMAs) has significantly changed the landscape of therapeutic options for MS patients. Many of these oral DMAs have demonstrated satisfactory safety and tolerability profiles in clinical trial settings, but the long-term safety of these agents is an important concern. This review discusses salient points on the safety and clinical efficacy of the approved and emerging novel oral therapies in RRMS, including fingolimod, teriflunomide, dimethyl fumarate, laquinimod, and cladribine.
UR - http://www.scopus.com/inward/record.url?scp=84880792302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880792302&partnerID=8YFLogxK
U2 - 10.1007/s40263-013-0080-z
DO - 10.1007/s40263-013-0080-z
M3 - Review article
C2 - 23801528
AN - SCOPUS:84880792302
SN - 1172-7047
VL - 27
SP - 591
EP - 609
JO - CNS Drugs
JF - CNS Drugs
IS - 8
ER -